Transplant recipients who develop cutaneous squamous cell carcinomas are at high risk for multiple subsequent skin cancers. Sirolimus has been shown to reduce the occurrence of secondary skin cancers, but no study included a follow-up exceeding 2 years. We extended at 5 years the TUMORAPA randomized trial of sirolimus-based immunosuppressive regimen versus calcineurin inhibitor-based immunosuppression.
INTRODUCTION
Cutaneous squamous cell carcinomas entail significant morbidity in organ transplant recipients. After the occurrence of a first lesion, the risk of developing subsequent skin cancers is up to 60% to 80% within 3 years. 1, 2 Changes in immunosuppressive regimens, including minimization, 3, 4 are a crucial part of a multidisciplinary approach to decrease the tumor burden of cutaneous squamous cell carcinomas and improve longterm survival. Randomized studies have shown that switching kidney transplant recipients with cutaneous squamous cell carcinoma from various immunosuppressive regimens to sirolimus significantly decreased the risk of new cutaneous squamous cell carcinomas when the conversion occurred early after a first squamous cell carcinoma. [5] [6] [7] [8] Nevertheless, none of them had follow-up exceeding 2 years, thereby resulting in uncertainty about the long-term benefit of this conversion.
Because data concerning the long-term effect of sirolimus on skin carcinomas are so far lacking, we extended the follow-up period of this randomized trial to analyze whether the substantial antitumoral benefit persisted up to 5 years.
METHODS

Eligibility
This study is a follow-up of the TUMORAPA randomized studies (TUMORAPA-1: patients with a first cutaneous squamous cell carcinoma; and TUMORAPA-N: patients with multiple cutaneous squamous cell carcinomas). The eligibility criteria, trial design, randomization, and treatment have been detailed previously. 5 The study included calcineurin inhibitor-treated adult kidney transplant recipients with stable kidney function who had developed at least one invasive post-transplant cutaneous squamous cell carcinoma.
Trial Design
This phase III multicenter randomized, open-label trial was conducted in accordance with the Declaration of Helsinki and ICH (International Conference on Harmonisation) good clinical practice, and approved by the local Research Ethics Committee (TUMORAPA-1 on February 23, 2004 , and TUMORAPA-N on June 1, 2004 ) and the French Health Products Safety Agency. The full study protocol and statistical analysis plan are available in a previous publication. 5 An amendment to increase the length of follow-up to 5 years was declared and approved on October 17, 2006 .
Trial Setting
The initial trial consisted of a 1:1 ratio for randomization in each study (TUMORAPA-1 and TUMORAPA-N) between continuation of calcineurin inhibitor-based therapy or conversion to sirolimus. All patients had to be followed up with dermatologic and nephrologic visits every 3 months the first 2 years then every 6 months until the 5-year mark (ie, 3 supplementary years) or the end of their participation in the study. All histologically proven skin tumors were counted. At each visit to the transplantation clinic, serum creatinine levels, 24-hour protein excretion, and sirolimus or calcineurin inhibitor blood levels were recorded.
End Points
The primary end point was survival free of new cutaneous squamous cell carcinomas at 5 years. Secondary end points included time of onset of new cutaneous squamous cell carcinomas, occurrence of other skin and nonskin (ie, internal) malignancies, graft function and outcome, patient and graft survival, and the effect of the minimization strategies on recurrence. For patients who dropped out of the study, information on the occurrence of metastatic cutaneous squamous cell carcinoma, internal tumors, and death was retrieved until the 5-year mark.
Study Oversight
The study was sponsored by the Hospices Civils de Lyon. Grants were received from the French ministry of Health, French Society of Dermatology, and Wyeth Pharmaceuticals. The manufacturer of sirolimus, Wyeth (now Pfizer) had no role in the trial design, collection, analysis, and interpretation of the data or writing of the report.
Statistical Analysis
From the 120 patients randomly assigned in the TUMORAPA studies, we defined an on-therapy population: all patients were considered as long as they were receiving assigned treatment. Data on cutaneous squamous cell carcinoma were considered up to 3 months after the end of the study to take into account any residual effect. We also defined a complete follow-up population comprising all patients who participated in the 5-year visit.
Analysis of the main end point (in the on-therapy population). Because of the timing of visits, survival was computed at time intervals rather than at precise times. We therefore used the %EMICM macro from SAS software (Version 9.2; SAS Institute, Cary, NC) on the basis of the EM algorithm of Turnbull to compute nonparametric maximum likelihood estimation to analyze the rate of survival free of new cutaneous squamous cell carcinomas. 9 We used the %ICS TEST macro from SAS 10,11 to obtain the generalized log-rank test to compare the two study groups. Crude hazard ratios on subgroups of patients with one or more than one cutaneous squamous cell carcinoma at the initial inclusion were obtained with the use of an accelerated failure-time model with interval censoring. SAS macros for analyzing interval-censored data are available at http:// support.sas.com/kb/24/980.html.
Analysis of the secondary end points (in the on-therapy population, unless otherwise specified). The number of patients with new cutaneous squamous cell carcinomas and new other skin tumors at 60 months (plus 3 months) were compared between groups using Fisher's exact test. To account for the varying study durations, we computed a mean annual number of skin tumors (number of new skin tumor/time of follow-up of patient). The occurrence of internal (ie, nonskin) cancer was recorded. Graft failures and rejections were noted. Graft function was assessed across time by means of graphics. We evaluated the patients' status (dead or alive) at 5 years. Patient survival was estimated using the Kaplan-Meier method in the on-protocol population.
Analyses were performed with the use of SAS software, version 9.2. A two-sided P value of .05 or less was considered statistically significant.
RESULTS
From March 2004 to March 2009, 120 kidney transplant recipients with at least one cutaneous squamous cell carcinoma, were assigned to receive sirolimus as a substitute for calcineurin inhibitors (n = 64) or to maintain their initial immunosuppressive treatment (n = 56). At 2 years, 88 patients were available to extend the study at 5 years, and 53 of them completed the 5-year follow-up with the treatment initially assigned (Fig 1) . The ontherapy population consisted of 120 randomly assigned patients with a median follow-up duration of 39.7 months (34.9 and 46.2 months in the sirolimus and the calcineurin inhibitor groups, respectively).
Survival free of cutaneous squamous cell carcinoma was significantly longer in the sirolimus group than in the calcineurin inhibitor group (P = .007; Fig 2) . When patients were studied in subgroups, this result remained significant only for patients with one cutaneous squamous cell carcinoma at randomization (crude hazard ratio, 0.20; 95% CI, 0.07 to 0.57; P = .001).
In the on-therapy population, new cutaneous squamous cell carcinomas developed in 14 and 33 patients in the sirolimus and calcineurin inhibitors groups, respectively (Table 1; 21.9% v 58.9%; P , .001; relative risk, 0.37; 95% CI, 0.22 to 0.61). The median interval time of occurrence after inclusion was 23.5 months in the sirolimus group compared with 12 months in the calcineurin inhibitors groups (P = .092). New other skin tumors (apart from squamous cell carcinomas) developed in 22 and 37 patients in the sirolimus and calcineurin inhibitor groups, respectively (34.4% v 66.1%; P = .001). Furthermore, the number of patients with new basal cell carcinomas was significantly lower in the sirolimus group (13 patients; 20.3%) compared with the calcineurin inhibitor group (21 patients; 37.5%; P = .044). The distribution of the skin tumors with the mean annual number per patient is listed in Table 1 . The same analysis was also performed on the 53 patients achieving the 5-year follow-up and confirmed the tendencies observed in the on-protocol population. Sirolimus jco.org treatment reduced the average number of cutaneous squamous cell carcinomas by 0.7, 0.4, and 0.5 lesions in the on-therapy population, on-protocol population with time adjustment, and complete follow-up population, respectively. For the complete follow-up population, the ratio of squamous to basal cell carcinomas decreased in both groups, but more importantly, in the sirolimus group (from 4.95 at inclusion to 1.26 over 5 years) than in the calcineurin inhibitor group (from 3.48 to 1.40).
Metastatic cutaneous squamous cell carcinoma developed in three patients while taking calcineurin inhibitors. One patient had been randomly assigned in the calcineurin inhibitor group 3 months before, but the two other patients had been initially in the sirolimus group for 2 and 18 months, respectively. In these two patients, metastatic cutaneous squamous cell carcinoma occurred after dropout and re-exposition to a calcineurin inhibitor for 6 months and 3 years, respectively.
Over the 5 years after randomization, 17 internal malignancies occurred (Table 2) in the whole studied population. Twelve malignancies were diagnosed while patients were taking therapy and five were diagnosed after dropping out. Among the seven patients included with a history of nonskin malignancies, none had a recurrence of their initial malignancy but two developed a new type of cancer (one during the study and one after dropping out).
Concerning graft function and outcomes, only two patients developed graft failure (one in each group). No episode of acute rejection occurred, and the mean serum creatinine or clearance according to modification of diet in renal disease formula remained stable during the study period in both groups (Figs A1A and A1B). The median value of daily proteinuria increased during the study period (Fig A1C) , but at 5 years, proteinuria was similar between the two groups (0.62 6 1.04 and 0.69 6 1.25 g/d in the sirolimus and calcineurin inhibitor groups, respectively).
Blood trough levels of sirolimus or calcineurin inhibitors remained within the predetermined ranges by the protocol throughout the study (Fig A2) . In the sirolimus group, trough levels were slightly higher in patients with new cutaneous squamous cell carcinomas compared with those without recurrence 
Withdrew consent Had adverse events Pneumonitis Aphthous ulcers Rash Edema Exercice dyspnea Mesenteric ishemia Discontinued for surgery Died: heart failure Dropped out of study (n = 11) (n = 2) (n = 8)
Withdrew consent Switched to sirolimus group because of cancer diagnosis Died: myocardial infarction (8.40 6 3.84 v 7.45 6 2.31 ng/mL at 5 years; P . .05). Minimization of other immunosuppressive drugs was performed during the study period in 75.5% of the patients in both groups (Table 3 ). In the sirolimus group, new cutaneous squamous cell carcinomas occurred in 23% of patients with minimization versus 45% in those without minimization. Such a finding was not observed in the calcineurin inhibitor group.
Nine patients died during the study period while patients were receiving therapy. Death was related to malignancy in two patients in each group. In addition, seven deaths (two in the sirolimus group and five in the calcineurin inhibitor group) occurred after dropout within the 5 years after inclusion. Patient survival 5 years after inclusion was 87.2% and 85% for the sirolimus and calcineurin inhibitor groups, respectively. Almost all sirolimus-treated patients had at least one drugrelated adverse event. Although adverse events (severe or not) led to discontinuation of sirolimus in 15 of 64 patients (23%) within 2 years, only seven additional patients (11%) had to discontinue sirolimus between 2 and 5 years, including in one patient to prevent postsurgery wound healing problems (Fig 1) . Furthermore, discontinuation of the calcineurin inhibitor was related in all patients (n = 19; 34%) to the occurrence of skin cancers or other jco.org malignancies, mostly diagnosed after 2 years. In the sirolimus group, 74 serious adverse events occurred in 64 patients (mean, 1.16 per patient) during the first 2 years, compared with 36 serious adverse events in 43 patients (mean, 0.83 per patient) between 2 and 5 years (Table 4) .
DISCUSSION
This research is an extension of the TUMORAPA study 5 and is the first prospective randomized study providing information at 5 years in kidney transplant recipients on the long-term efficacy and safety of the conversion from calcineurin inhibitors to a sirolimus-based immunosuppressive regimen for the secondary prevention of cutaneous squamous cell carcinomas. Our results clearly show that the beneficial effect of conversion to sirolimus is maintained at 5 years. We chose to study the on-therapy population considering that a pure intention-to-treat analysis over 5 years would imply examining various patients trajectories. However, our main analysis considered survival, therefore enabling us to account for time inclusion in the study. In this on-therapy study, conversion to sirolimus was associated with a significant reduction in the number of patients with new cutaneous squamous cell carcinomas and in the cumulative number of new cutaneous squamous cell carcinomas compared with patients maintained with calcineurin inhibitor-based immunosuppression. The prevention of cutaneous squamous cell carcinoma recurrence with sirolimus was only significant in the group of patients with a single squamous cell carcinoma at inclusion. In addition, conversion to sirolimus was associated with a significant reduction of the number of patients with new basal cell carcinoma (s), although in a smaller proportion compared with patients with new squamous cell carcinoma. Different mechanisms of oncogenesis 12 for squamous and basal cell carcinomas, especially concerning the mammalian target of rapamycin (mTOR) pathway, 13 could explain the different sensitivity of these skin malignancies to sirolimus. We observed an obvious reduction in the squamous to basal cell carcinoma ratio in patients taking sirolimus, but a moderate decrease was also found in patients treated with calcineurin inhibitors, probably because of their close immunologic and dermatologic monitoring. Evaluation of the two patient groups who completed the 5-year follow-up showed a trend toward a lower rate of all skin tumors in the sirolimus versus the calcineurin inhibitor group. The reason this difference did not prove statistically significant is probably because patients maintained in the latter group were those with fewer cutaneous squamous cell carcinomas. The number of patients with metastatic cutaneous squamous cell carcinoma in the study was rather low (2.5%) but ranged in the figures in the literature. 14 Although no metastatic course occurred in patients taking sirolimus, no conclusion can be drawn because of the few number of events.
Although immunosuppression minimization is generally considered able to decrease the occurrence of new skin cancers, our findings show that for patients already taking a low dosage of calcineurin inhibitor (as requested in this study in the inclusion criteria), the rate of cutaneous squamous cell carcinoma recurrence was not further reduced by minimization of other immunosuppressive treatments. This observation suggests that calcineurin inhibitors exert a prevailing deleterious effect on the development of skin carcinomas.
We did not observe any difference in the rate of internal (ie, noncutaneous) cancers, as suggested in previous studies. 15, 16 However, the distribution of some cancers could be modified in patients treated with sirolimus, with a decreased incidence of kidney cancer 17 and an increased incidence of low-grade prostate cancer. 18 Despite the insufficient size of our cohort (which does not allow firm conclusions to be drawn), we observed three patients with prostate cancer in the sirolimus group and one patient with kidney cancer in the calcineurin inhibitor group. Interestingly, two recent studies showed that in kidney 19 and solid-organ transplant recipients, 20 the adjusted risk to develop internal malignancy ranged between 1.44 and 3.0 for those recipients with prior cutaneous squamous cell carcinoma. In addition, the risks were particularly elevated for noncutaneous squamous cell cancer and other human papillomavirus-related cancers (ie, oral cavity/pharyngeal cancers, lip cancer, tongue cancer, and lung cancer), 20 suggesting some shared etiologies for these carcinomas in the setting of immunosuppression. Indeed, it should be hypothesized that in the transplant-recipient population, the reduction of cutaneous squamous cell carcinoma with the use of mTOR inhibitors could be associated with a reduced or delayed occurrence of nonskin squamous cell malignancies.
The relative contributions of calcineurin inhibitor withdrawal versus the introduction of sirolimus to the decrease in cutaneous squamous cell carcinoma recurrence remains difficult to assess. The withdrawal of calcineurin inhibitors and the minimization of other immunosuppressive drugs are likely important, because there is compelling evidence for carcinogenic mechanisms associated with calcineurin inhibitors 21, 22 and azathioprine. 23 The deleterious effect of cyclosporine on skin carcinogenesis has been largely investigated and, in addition to the loss of tumor immunosurveillance against human papillomavirus infection 24 (that is inherent to all immunosuppressive drugs), cyclosporine exerts immune-independent mechanisms favoring skin tumorigenesis through alteration of DNA repair, 25 inhibition of calcineurinnuclear factor of activated T cells signaling leading to ATF3-dependent suppression of p53, 26 and promotion of the angiogenesis. 27 However, it seems that at the dose used in organ transplant recipients, skin carcinomas are a preferential target for mTOR inhibitors compared with internal malignancies. 28, 29 mTOR-mediated anticancer mechanisms in transplant recipients are probably partly the result of inhibition of tumor vascularization more than a direct inhibition of tumor-intrinsic mTOR activation. 30 Indeed, it has been shown that conversion from calcineurin inhibitors to sirolimus reduces the vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
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In addition, concerning skin carcinogenesis, mTOR inhibitors could inhibit the signaling of the oncoprotein E6 of the human papillomavirus-16, 32 alter ultraviolet B-induced P53 mutations, 33 inhibit tumor-associated ion channel activity, 34 and change Akt signaling. 35 Finally, it has been suggested in registries that combination therapy with calcineurin inhibitors and sirolimus could also decrease the occurrence of de novo cancer, suggesting a specific beneficial effect of sirolimus not only on skin cancer (and not merely an effect due to calcineurin inhibitor withdrawal 15, 36 ). Nevertheless, so far, no data exist on a direct comparison between sirolimus and sirolimus/calcineurin inhibitor-based regimens in the secondary prevention of skin carcinoma.
The benefit of the conversion must be weighed against treatment tolerance. The risk of adverse effects decreases with time but is not limited to the early postconversion period. At 2 years, the rate of dropouts in the sirolimus group due to its usual adverse effects was similar to other reported series, 6, 7 and between 2 and 5 years, only a few additional patients had to be excluded. Our study was initiated in 2004, and numerous factors, that could be now avoided, contributed to a high dropout rate, including abruptness of the conversion, use of loading doses, and high drug blood concentrations. 37 Importantly, although still debated, an increased risk of de novo donor-specific antibodies 38,39 and of global mortality rate 29, 40 were reported with the use of de novo or early conversion to an mTOR inhibitorbased regimen. Such findings were not confirmed in our study (donor-specific immunization was retrospectively detected in 9.8% and 18.6% of the patients tested in the sirolimus and the calcineurin inhibitor groups, respectively), as well as in those of late conversion. 39 Finally, we did not observe acute rejections, as in other studies of late conversion. 28, 41 We confirm that at 5 years, conversion to sirolimus significantly reduces the risk of developing new cutaneous squamous cell carcinoma compared with maintaining calcineurin inhibitors. The earlier the conversion the greater is its efficacy, with no negative effect on the long-term follow-up regarding graft and patient survival. Despite a non-negligible rate of adverse events, which can be reduced by progressive protocols, this immunosuppressive strategy should be recommended for kidney transplant patients taking calcineurin inhibitors after the occurrence of the first cutaneous squamous cell carcinoma. Future effort should aim at defining the subgroup of patients with the highest probability of drug tolerance and/or efficacy of late conversion 42 and also at defining the potential efficacy in the prevention of cutaneous squamous cell carcinoma recurrence of the more recently proposed dual therapies combining mTOR inhibitors and low-dose calcineurin inhibitors. Mean trough levels of immunosuppressive drugs in the (A) sirolimus (ng/mL) and calcineurine inhibitor groups, (B) cyclosporine and (C) tacrolimus (ng/mL), for patients both with and without new squamous cell carcinoma (SCC) after being randomly assigned in the on-protocol population.
